AN2 Therapeutics (ANTX) Other Accumulated Expenses (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Other Accumulated Expenses of $567000.0 for Q1 2026, up 829.51% year-over-year from $61000.0 in Q1 2025, and up 1034.0% quarter-over-quarter from $50000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Other Accumulated Expenses for 6 consecutive years, with $567000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 829.51% year-over-year to $567000.0; the TTM figure through Mar 2026 stood at $567000.0 (up 829.51% YoY), while the FY2025 annual figure was $50000.0, down 1.96% from the prior year.
- Other Accumulated Expenses climbed to $567000.0 in Q1 2026 per ANTX's latest filing, from $50000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.3 million in Q3 2024 and bottomed at $9000.0 in Q2 2022.
- Historically, Other Accumulated Expenses has averaged $315333.3 across 5 years, with a median of $61000.0 in 2025.
- On a YoY basis, Other Accumulated Expenses climbed as much as 1529.55% in 2025 and fell as far as 97.41% in 2025.
- AN2 Therapeutics' Other Accumulated Expenses stood at $122000.0 in 2022, then soared by 445.9% to $666000.0 in 2023, then slumped by 92.34% to $51000.0 in 2024, then dropped by 1.96% to $50000.0 in 2025, then surged by 1034.0% to $567000.0 in 2026.
- Business Quant data shows ANTX's Other Accumulated Expenses at $567000.0 in Q1 2026, $50000.0 in Q4 2025, and $33000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 776,000.00 |
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | 183,000.00 |
| Jun 30, 2025 | 717,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 791,000.00 |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 559,000.00 |
| Mar 31, 2024 | 321,000.00 |
| Dec 31, 2023 | 666,000.00 |
| Sep 30, 2023 | 973,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 122,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 41,000.00 |